Tardive syndromes are late-onset movement disorders from chronic dopamine D2 blockade. The mechanism: chronic D2 antagonism produces receptor supersensitivity (upregulation of D2 receptors, increased sensitivity to dopaminergic input). When the system is exposed to even normal dopaminergic activity, hyperresponsiveness produces involuntary movements.
Major tardive syndromes:
Tardive dyskinesia (TD) — most common. Involuntary repetitive movements, classically oral-buccal-lingual (lip-smacking, tongue protrusion and twisting, chewing-like movements, grimacing). Can involve limbs (choreiform movements), trunk, breathing pattern. Often emerges or worsens when antipsychotic dose is reduced.
Tardive dystonia — sustained involuntary postures. More common in younger patients. Often more disabling than TD.
Tardive akathisia — persistent inner restlessness, urge to move, can be agitating and distressing. Distinguished from acute akathisia by chronicity and persistence after medication change.
Tardive tics — relatively rare.
Tardive tremor — relatively rare.
Risk factors: longer duration of antipsychotic exposure, higher doses, first-generation (high D2 affinity) antipsychotics, older age, female sex, history of brain injury, intellectual disability, mood disorder rather than schizophrenia diagnosis, intermittent (rather than continuous) dosing. Risk increases with duration; some patients develop TD after years of stable treatment.
Prevention: use the minimum effective antipsychotic dose. Consider second-generation antipsychotics (lower TD risk than first-generation but not zero risk). Avoid unnecessary antipsychotic use (particularly off-label for behavioral symptoms in dementia, mild anxiety, sleep). Periodic AIMS scale assessment in patients on long-term antipsychotic therapy.
Recognition: AIMS (Abnormal Involuntary Movement Scale) is the standard screening tool — should be performed at baseline before starting antipsychotic and every 6 months thereafter. Patient and family education about what to watch for.
Treatment:
VMAT2 inhibitors — first FDA-approved treatments for TD: valbenazine (Ingrezza) 40-80 mg daily, deutetrabenazine (Austedo) 12-48 mg daily in divided doses. Substantial efficacy; well-tolerated. Mechanism: deplete presynaptic dopamine release through VMAT2 inhibition, reducing the hyperresponsive postsynaptic dopaminergic signaling.
Reduce or switch antipsychotic when possible. Note: abrupt withdrawal can transiently worsen TD before improving. Switch to lower-D2-affinity agent: clozapine has lowest TD risk and may even improve existing TD; quetiapine and ziprasidone are intermediate.
Older interventions: tetrabenazine (also VMAT2 inhibitor — older, more dosing complexity), branched-chain amino acids, ginkgo biloba (small evidence), vitamin E (limited benefit), clonazepam (modest).
Considerations: some TD persists despite optimal treatment. Continued antipsychotic indication often requires balancing psychiatric stability against ongoing TD. Clozapine often the best long-term solution when antipsychotic continuation is needed.
When you encounter a patient with involuntary movements on long-term antipsychotic therapy, TD is the diagnosis. The VMAT2 inhibitors have transformed treatment options. Consider switching antipsychotic. Document AIMS findings. The disorder is partially preventable through prudent prescribing.